{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:03Z","timestamp":1794047463890,"version":"4.8.0"},"reference-count":54,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) is an incurable plasma cell malignancy that, despite an unprecedented increase in overall survival, lacks truly risk-adapted or targeted treatments. A proportion of patients with MM depend on BCL-2 for survival, and, recently, the BCL-2 antagonist venetoclax has shown clinical efficacy and safety in t(11;14) and BCL-2 overexpressing MM. However, only a small proportion of MM patients rely on BCL-2 (approx. 20%), and there is a need to broaden the patient population outside of t(11;14) that can be treated with venetoclax. Therefore, we took an unbiased screening approach and screened epigenetic modifiers to enhance venetoclax sensitivity in 2 non-BCL-2 dependent MM cell lines. The demethylase inhibitor 5-azacytidine was one of the lead hits from the screen, and the enhanced cell killing of the combination was confirmed in additional MM cell lines. Using dynamic BH3 profiling and immunoprecipitations, we identified the potential mechanism of synergy is due to increased NOXA expression, through the integrated stress response. Knockdown of PMAIP1 or PKR partially rescues cell death of the venetoclax and 5-azacytidine combination treatment. The addition of a steroid to the combination treatment did not enhance the cell death, and, interestingly, we found enhanced death of the immune cells with steroid addition, suggesting that a steroid-sparing regimen may be more beneficial in MM. Lastly, we show for the first time in primary MM patient samples that 5-azacytidine enhances the response to venetoclax ex vivo across diverse anti-apoptotic dependencies (BCL-2 or MCL-1) and diverse cytogenetic backgrounds. Overall, our data identify 5-azacytidine and venetoclax as an effective treatment combination, which could be a tolerable steroid-sparing regimen, particularly for elderly MM patients.<\/jats:p>","DOI":"10.3324\/haematol.2023.283771","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T07:05:15Z","timestamp":1711004715000},"page":"2930-2943","source":"Crossref","is-referenced-by-count":3,"title":["Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Lyndsey","family":"Flanagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Drozdz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Comerford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Minihane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Parvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Furney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Glavey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tr\u00edona N\u00ed","family":"Chonghaile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leukemia Research","family":"Foundation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Science Foundation","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breakthrough Cancer","family":"Research","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"65855","unstructured":"Cancer Factsheet Multiple Myeloma (ICD-10 C90) NCRI. 2023. Publisher Full Text|"},{"key":"65856","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020; 95(5):548-567.","DOI":"10.1002\/ajh.25791"},{"key":"65857","doi-asserted-by":"crossref","unstructured":"Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic \/ racial groups: support for genetic factors in pathogenesis. Leukemia. 2009; 23(10):1691-1697.","DOI":"10.1038\/leu.2009.134"},{"key":"65858","doi-asserted-by":"crossref","unstructured":"Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015; 125(20):3076-3084.","DOI":"10.1182\/blood-2014-09-568915"},{"key":"65859","doi-asserted-by":"crossref","unstructured":"Maji S, Panda S, Samal SK. Bcl-2 antiapoptotic family proteins and chemoresistance in cancer. Adv Cancer Res. 2018; 137:37-75.","DOI":"10.1016\/bs.acr.2017.11.001"},{"key":"65860","doi-asserted-by":"crossref","unstructured":"Ni Chonghaile T, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene. 2008; 27(Suppl 1):S149-S157.","DOI":"10.1038\/onc.2009.52"},{"key":"65861","doi-asserted-by":"crossref","unstructured":"Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002; 2(9):647-656.","DOI":"10.1038\/nrc883"},{"key":"65862","doi-asserted-by":"crossref","unstructured":"Wuilleme-Toumi S, Robillard N, Gomez P. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005; 19(7):1248-1252.","DOI":"10.1038\/sj.leu.2403784"},{"key":"65863","doi-asserted-by":"crossref","unstructured":"Thomas RL, Roberts DJ, Kubli DA. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013; 27(12):1365-1377.","DOI":"10.1101\/gad.215871.113"},{"key":"65864","doi-asserted-by":"crossref","unstructured":"Wang X, Bathina M, Lynch J. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013; 27(12):1351-1364.","DOI":"10.1101\/gad.215855.113"},{"key":"65865","doi-asserted-by":"crossref","unstructured":"Roberts AW, Davids MS, Pagel JM. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016; 374(4):311-322.","DOI":"10.1056\/NEJMoa1513257"},{"key":"65866","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Stein EM, de Botton S. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018; 378(25):2386-2398.","DOI":"10.1056\/NEJMoa1716984"},{"key":"65867","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz K, Pullarkat V. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019; 133(1):7-17.","DOI":"10.1182\/blood-2018-08-868752"},{"key":"65868","doi-asserted-by":"crossref","unstructured":"Bodet L, Gomez-Bougie P, Touzeau C. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood. 2011; 118(14):3901-3910.","DOI":"10.1182\/blood-2010-11-317438"},{"key":"65869","doi-asserted-by":"crossref","unstructured":"Touzeau C, Dousset C, Le Gouill S. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014; 28(1):210-212.","DOI":"10.1038\/leu.2013.216"},{"key":"65870","doi-asserted-by":"crossref","unstructured":"Kumar S, Kaufman JL, Gasparetto C. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017; 130(22):2401-2409.","DOI":"10.1182\/blood-2017-06-788786"},{"key":"65871","doi-asserted-by":"crossref","unstructured":"Kumar S, Harrison SJ, Cavo M. Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/ refractory multiple myeloma. Blood. 2021; 138(Suppl 1):84.","DOI":"10.1182\/blood-2021-145757"},{"key":"65872","doi-asserted-by":"crossref","unstructured":"Bal S, Kumar SK, Fonseca R. Multiple myeloma with t(11;14): unique biology and evolving landscape. Am J Cancer Res. 2022; 12(7):2950-2965.","DOI":"10.3390\/cancers14122965"},{"key":"65873","doi-asserted-by":"crossref","unstructured":"Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008; 123(1):8-13.","DOI":"10.1002\/ijc.23607"},{"key":"65874","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz KW, Letai A. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018; 19(2):216-228.","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"65875","doi-asserted-by":"crossref","unstructured":"Benito JM, Godfrey L, Kojima K. MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. Cell Rep. 2015; 13(12):2715-2727.","DOI":"10.1016\/j.celrep.2015.12.003"},{"key":"65876","doi-asserted-by":"crossref","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364(11):1046-1060.","DOI":"10.1056\/NEJMra1011442"},{"key":"65877","doi-asserted-by":"crossref","unstructured":"Caenepeel S, Brown SP, Belmontes B. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018; 8(12):1582-1597.","DOI":"10.1158\/2159-8290.CD-18-0387"},{"key":"65878","doi-asserted-by":"crossref","unstructured":"Foight GW, Ryan JA, Gulla SV, Letai A, Keating AE. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol. 2014; 9(9):1962-1968.","DOI":"10.1021\/cb500340w"},{"key":"65879","doi-asserted-by":"crossref","unstructured":"Touzeau C, Ryan J, Guerriero J. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016; 30(3):761-764.","DOI":"10.1038\/leu.2015.184"},{"key":"65880","doi-asserted-by":"crossref","unstructured":"Tse C, Shoemaker AR, Adickes J. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008; 68(9):3421-3428.","DOI":"10.1158\/0008-5472.CAN-07-5836"},{"key":"65881","doi-asserted-by":"crossref","unstructured":"Chonghaile TN, Roderick JE, Glenfield C. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014; 4(9):1074-1087.","DOI":"10.1158\/2159-8290.CD-14-0353"},{"key":"65882","doi-asserted-by":"crossref","unstructured":"Liu T, Stephan T, Chen P. Multi-color live-cell STED nanoscopy of mitochondria with a gentle inner membrane stain. Proc Natl Acad Sci U S A. 2022; 119(52):e2215799119.","DOI":"10.1073\/pnas.2215799119"},{"key":"65883","doi-asserted-by":"crossref","unstructured":"Vincent T, Mechti N. Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leuk Lymphoma. 2005; 46(6):803-811.","DOI":"10.1080\/10428190500051448"},{"key":"65884","doi-asserted-by":"crossref","unstructured":"Jin S, Cojocari D, Purkal JJ. 5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res. 2020; 26(13):3371-3383.","DOI":"10.1158\/1078-0432.CCR-19-1900"},{"key":"65885","doi-asserted-by":"crossref","unstructured":"Sidrauski C, Acosta-Alvear D, Khoutorsky A. Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife. 2013; 2:e00498.","DOI":"10.7554\/eLife.00498"},{"key":"65886","doi-asserted-by":"crossref","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015; 162(5):974-986.","DOI":"10.1016\/j.cell.2015.07.011"},{"key":"65887","doi-asserted-by":"crossref","unstructured":"Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ. 2020; 370:m3176.","DOI":"10.1136\/bmj.m3176"},{"key":"65888","doi-asserted-by":"crossref","unstructured":"Khaw SL, Merino D, Anderson MA. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014; 28(6):1207-1215.","DOI":"10.1038\/leu.2014.1"},{"key":"65889","doi-asserted-by":"crossref","unstructured":"Ludwig LM, Hawley KM, Banks DB. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death Dis. 2021; 12(11):1005.","DOI":"10.1038\/s41419-021-04285-4"},{"key":"65890","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Rausch CR, Benton C. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018; 93(3):401-407.","DOI":"10.1002\/ajh.25000"},{"key":"65891","doi-asserted-by":"crossref","unstructured":"Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006; 5(1):37-50.","DOI":"10.1038\/nrd1930"},{"key":"65892","doi-asserted-by":"crossref","unstructured":"Roulois D, Loo Yau H, Singhania R. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015; 162(5):961-973.","DOI":"10.1016\/j.cell.2015.07.056"},{"key":"65893","doi-asserted-by":"crossref","unstructured":"Patel JR, Jain A, Chou YY. ATPase-driven oligomerization of RIG-I on RNA allows optimal activation of type-I interferon. EMBO Rep. 2013; 14(9):780-787.","DOI":"10.1038\/embor.2013.102"},{"key":"65894","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020; 10(9):94.","DOI":"10.1038\/s41408-020-00359-2"},{"key":"65895","doi-asserted-by":"crossref","unstructured":"Matulis SM, Gupta VA, Nooka AK. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia. 2016; 30(5):1086-1093.","DOI":"10.1038\/leu.2015.350"},{"key":"65896","doi-asserted-by":"crossref","unstructured":"Matulis SM, Gupta VA, Neri P. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia. 2019; 33(5):1291-1296.","DOI":"10.1038\/s41375-018-0374-8"},{"key":"65897","unstructured":"AbbVie presents results from phase 3 CANOVA study of venetoclax in patients with relapsed or refractory multiple myeloma. News release. AbbVie. September 29. 2023. Publisher Full Text|"},{"key":"65898","doi-asserted-by":"crossref","unstructured":"Veis DJ, Sentman CL, Bach EA, Korsmeyer SJ. Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes. J Immunol. 1993; 151(5):2546-2554.","DOI":"10.4049\/jimmunol.151.5.2546"},{"key":"65899","doi-asserted-by":"crossref","unstructured":"Rohner L, Reinhart R, Iype J. Impact of BH3-mimetics on human and mouse blood leukocytes: a comparative study. Sci Rep. 2020; 10(1):222.","DOI":"10.1038\/s41598-019-57000-x"},{"key":"65900","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Jacobus S, Callander NS. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010; 11(1):29-37.","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"65901","doi-asserted-by":"crossref","unstructured":"Manier S, Corre J, Hulin C. A dexamethasone-sparing regimen with daratumumab and lenalidomide in frail patients with newly-diagnosed multiple myeloma: efficacy and safety analysis of the phase 3 IFM2017-03 trial. Blood. 2022; 140(Suppl 1):1369.","DOI":"10.1182\/blood-2022-159933"},{"key":"65902","doi-asserted-by":"crossref","unstructured":"Gomez-Bougie P, Maiga S, Tessoulin B. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood. 2018; 132(25):2656-2669.","DOI":"10.1182\/blood-2018-03-836718"},{"key":"65903","doi-asserted-by":"crossref","unstructured":"Glavey SV, Flanagan L, Bleach R. Secondary plasma cell leukaemia treated with single agent venetoclax. Br J Haematol. 2020; 190(4):e242-e245.","DOI":"10.1111\/bjh.16858"},{"key":"65904","doi-asserted-by":"crossref","unstructured":"Di Grande A, Peirs S, Donovan PD. The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL. Blood Adv. 2021; 5(7):1963-1976.","DOI":"10.1182\/bloodadvances.2021004177"},{"key":"65905","doi-asserted-by":"crossref","unstructured":"Sullivan GP, Flanagan L, Rodrigues DA, Ni Chonghaile T. The path to venetoclax resistance is paved with mutations, metabolism, and more. Sci Transl Med. 2022; 14(674):eabo6891.","DOI":"10.1126\/scitranslmed.abo6891"},{"key":"65906","doi-asserted-by":"crossref","unstructured":"Ni Chonghaile T, Sarosiek KA, Vo TT. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011; 334(6059):1129-1133.","DOI":"10.1126\/science.1206727"},{"key":"65907","doi-asserted-by":"crossref","unstructured":"Bhatt S, Pioso MS, Olesinski EA. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell. 2020; 38(6):872-890.","DOI":"10.1016\/j.ccell.2020.10.010"},{"key":"65908","doi-asserted-by":"crossref","unstructured":"Gupta VA, Matulis SM, Barwick BG. Venetoclax ex vivo functional profiling predicts improved progression-free survival. Blood Cancer J. 2022; 12(8):115.","DOI":"10.1038\/s41408-022-00710-9"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283771\/76749","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283771\/77432","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11511\/76749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:00Z","timestamp":1794045960000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283771","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,21]]}}}